The monoclonal HBA-71 antibody modulates proliferation of thymocytes and Ewing's sarcoma cells by interfering with the action of insulin-like growth factor I
- PMID: 1656551
The monoclonal HBA-71 antibody modulates proliferation of thymocytes and Ewing's sarcoma cells by interfering with the action of insulin-like growth factor I
Abstract
The monoclonal HBA-71 antibody recognizes a Ewing's sarcoma associated antigen, which is also highly expressed on the cell surface of human cortical thymocytes and islets of Langerhans among normal tissues. The antibody was found to inhibit partially the growth of ES tumor cell lines and to trigger proliferation in thymocyte cultures. The influence of growth factors and the effect of the HBA-71 antibody was further investigated in the present study. The growth of ES tumor cells was demonstrated to be dependent on the presence of insulin-like growth factor I or insulin. The HBA-71 antibody (25 micrograms/ml) enhanced the growth stimulatory effect of IGF-I under serum-free conditions. The expression of the HBA-71 epitope is modulated positively by IGF-I and insulin and negatively by dexamethasone and human growth hormone in ES/PNET tumor cells and thymocytes. IGF-I either alone or in combination with HBA-71 stimulated the proliferation of thymocytes under serum-free conditions whereas in complete medium, IGF-I stimulated thymidine incorporation and the HBA-71 antibody either alone or in the presence of IGF-I showed inhibitory activity most likely due to down-regulation of the receptor. These data demonstrate the important role of IGF-I in the growth of ES/PNET tumor cells as well in the proliferative activity of HBA-71 positive normal thymocytes. The biological activity of IGF-I in malignant thymocytes, pancreas tumors, fetal muscle, brain, granulosa and Sertoli cells has been documented in the literature.(ABSTRACT TRUNCATED AT 250 WORDS)
Similar articles
-
Characterization of a human endocrine tissue and tumor-associated Ewing's sarcoma antigen.Cancer Res. 1988 Nov 1;48(21):6127-31. Cancer Res. 1988. PMID: 2844401
-
Inhibition of proliferation in human MNNG/HOS osteosarcoma and SK-ES-1 Ewing sarcoma cell lines in vitro and in vivo by antagonists of growth hormone-releasing hormone: effects on insulin-like growth factor II.Cancer. 2002 Oct 15;95(8):1735-45. doi: 10.1002/cncr.10865. Cancer. 2002. PMID: 12365022
-
In vitro antiproliferative effects of albumin-doxorubicin conjugates against Ewing's sarcoma and peripheral neuroectodermal tumor cells.Anticancer Res. 1994 Sep-Oct;14(5A):1943-50. Anticancer Res. 1994. PMID: 7847832
-
[Structure of the receptor for insulin-like growth factors].Seikagaku. 1984 Apr;56(4):235-45. Seikagaku. 1984. PMID: 6090548 Review. Japanese. No abstract available.
-
Polypeptide growth factors: their potential value in the management of breast cancer patients.Cancer Treat Res. 1992;60:315-29. doi: 10.1007/978-1-4615-3496-9_15. Cancer Treat Res. 1992. PMID: 1355995 Review. No abstract available.
Cited by
-
PI3K/AKT signaling modulates transcriptional expression of EWS/FLI1 through specificity protein 1.Oncotarget. 2015 Oct 6;6(30):28895-910. doi: 10.18632/oncotarget.5000. Oncotarget. 2015. PMID: 26336820 Free PMC article.
-
Potential molecular targets for Ewing's sarcoma therapy.Indian J Med Paediatr Oncol. 2012 Oct;33(4):195-202. doi: 10.4103/0971-5851.107074. Indian J Med Paediatr Oncol. 2012. PMID: 23580819 Free PMC article.
-
The emerging role of mammalian target of rapamycin inhibitors in the treatment of sarcomas.Target Oncol. 2011 Mar;6(1):29-39. doi: 10.1007/s11523-011-0179-4. Epub 2011 Apr 28. Target Oncol. 2011. PMID: 21533543 Review.
-
Role of immunotherapy in Ewing sarcoma.J Immunother Cancer. 2020 Dec;8(2):e000653. doi: 10.1136/jitc-2020-000653. J Immunother Cancer. 2020. PMID: 33293354 Free PMC article. Review.
-
Exploiting Signaling Pathways and Immune Targets Beyond the Standard of Care for Ewing Sarcoma.Front Oncol. 2019 Jun 19;9:537. doi: 10.3389/fonc.2019.00537. eCollection 2019. Front Oncol. 2019. PMID: 31275859 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Miscellaneous